Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Net (2021 - 2024)

Zentalis Pharmaceuticals has reported Receivables - Net over the past 2 years, most recently at $5.0 million for Q4 2024.

  • For Q4 2024, Receivables - Net changed N/A year-over-year to $5.0 million; the TTM value through Dec 2024 reached $5.0 million, changed N/A, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Receivables - Net for Q4 2024 was $5.0 million at Zentalis Pharmaceuticals, up from $4000.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $5.0 million in Q4 2024 and troughed at $4000.0 in Q4 2021.